• News
  • SAN DIEGO
  • Health

Genoa teams up with McMaster University

Genoa Pharmaceuticals Inc. and McMaster University announced a plan to collaborate on idiopathic pulmonary fibrosis (IPF) research.

San Diego-based Genoa, which works in the field of pulmonary fibrosis, will work with researchers to characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF.

"We are very interested to evaluate novel therapies such as GP-101 to better understand the molecular effects and in vivo relationship to the human disease," said Dr. Martin Kolb, associate professor in the Division of Respirology, within the Department of Medicine Pathology & Molecular Medicine at McMaster University in Canada.

The research will combine Genoa's expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.

"Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients," said Mark Surber, Ph.D., Genoa's founder, president and chief scientific officer. "Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF."

RELATED ARTICLES:

Velocity taps EuMederis for drug program

Sanford-Burnham's CEO resigns

La Jolla Pharmaceutical expands team

Victory Pharma to pay $11.4 million to settle kickback claim

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.